Mundipharma Pty Limited (Mundipharma) has added two innovative physical therapy devices to its pain management portfolio, acquiring the exclusive Australian and New Zealand rights to the PAINmate® and ActiPatch® brands from Evomed Pty Limited (Evomed).

“Mundipharma is committed to the multimodal approach to pain management, which includes Cognitive Behavioural Therapies, Physical Therapies and Pharmacological Therapies,” said Jane Orr, Managing Director of Mundipharma Australia and New Zealand.

“The addition of two innovative physical therapy devices to our existing pain medications reaffirms our commitment to help clinicians manage pain in a stepped, multimodal approach.”

The two physical therapy devices are:
PAINmate® – A portable, wireless and affordable device that sends electrical nerve stimulation through the skin to provide fast and targeted pain relief, and
ActiPatch® – A device that dampens the brain’s perception of pain by stimulating nerve activity with electromagnetic pulses.

ActiPatch and PainMate

“Our pain management education programs for healthcare professionals emphasise the Quality Use of Medications and the importance of multimodal pain management, so I’m very proud that we’re now able to offer more products that support the multimodal approach,” Ms Orr said.

“PAINmate® and Actipatch® are already helping many people living with pain enjoy a better quality of life and we look forward to helping even more Australians do the same.”

The deal also includes exclusive Australian and New Zealand distribution rights for AccuVein®, a device that digitally displays a map of blood vessels on the surface of the skin in real time.

“AccuVein® will help us deliver significant benefits for our customers and patients, as it already does in more than 100 countries and clinical settings including oncology, emergency, paediatrics, blood banks, haematology, phlebology and operating theatres to name a few.”

This deal continues the growth and diversification of Mundipharma’s product portfolio, following this year’s launch of mundicare® Cold Defence, the acquisition of a prostate cancer medication and the PBS listing of a medication for Peripheral T-Cell Lymphoma.

Mundipharma’s portfolio now includes 36 effective health care products across pain, oncology, ophthalmology, respiratory, first aid, hydration and the common cold.

“Part of our growth and diversification strategy is to acquire profitable businesses and products, and this deal proves that we remain ready, willing and able to do just that,” Ms Orr said. “We will also continue to bring products to Australia and New Zealand through our global network of independent associated companies.”

“This network, combined with our local autonomy and agility, is critical to our continued growth and success, and our ability to invest in long term value for our patients, customers and business partners.”